BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, August 6, 2012
At least 26 biotechs and pharmas reported earnings
last week. Shares of Incyte Corp. (NASDAQ:INCY) fell 28% on the week,
losing more than $900 million in market value. The company, which started
selling Jakafi ruxolitinib last year for myelofibrosis, posted EPS and revenues
that surpassed analyst consensus estimates. However, investors had trouble
digesting the company's change in how it recognizes revenue in light of newly
introduced 2012 sales guidance for Jakafi.
Anika Therapeutics Inc. (NASDAQ:ANIK) and Repligen
Inc. (NASDAQ:RGEN) were up more than 15% last week after beating the
Street's EPS and revenue estimates. Anika markets Orthovisc high molecular
weight hyaluronan. Repligen supplies products for manufacturing biologics, and
last week said it would focus on its bioprocessing business and seek partners
for it internally developed biologic therapeutics. (A) Fiscal 1Q; (B) Estimate
from one analyst; (C) Fiscal 4Q; Mcap in $M
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]